Search Tag: ATTR-CM Study

2024 30 Aug

  Vutrisiran significantly reduced mortality, cardiovascular events, and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented today in a Hot Line session at ESC Congress 2024.   ATTR is a progressive, fatal disease characterised by the accumulation...Read more